Kazia Therapeutics Dividends and Buybacks
Dividend criteria checks 0/6
Kazia Therapeutics does not have a record of paying a dividend.
Key information
n/a
Dividend yield
-29.3%
Buyback Yield
| Total Shareholder Yield | -29.3% |
| Future Dividend Yield | n/a |
| Dividend Growth | n/a |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Payout ratio | n/a |
Recent dividend and buyback updates
No updates
Recent updates
Kazia gains on FDA’s rare pediatric disease designation for childhood cancer therapy
Jul 06Kazia enters clinical collaboration with Cornell University for mid-stage glioblastoma trial
Jun 15Enrollment gets underway in Kazia's mid-stage lymphoma study
Jun 07Kazia, Pacific Pediatric Neuro-Oncology collaborate for paxalisib combo study in type of brain cancer
Dec 10Kazia Therapeutics -2% on cantrixil data in early-stage ovarian cancer study
Dec 09Kazia stock +22% on positive paxalisib data in glioblastoma
Nov 18Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if KZIA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if KZIA's dividend payments have been increasing.
Dividend Yield vs Market
| Kazia Therapeutics Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (KZIA) | n/a |
| Market Bottom 25% (US) | 1.4% |
| Market Top 25% (US) | 4.5% |
| Industry Average (Biotechs) | 2.4% |
| Analyst forecast (KZIA) (up to 3 years) | n/a |
Notable Dividend: Unable to evaluate KZIA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate KZIA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate KZIA's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as KZIA has not reported any payouts.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 02:58 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Kazia Therapeutics Limited is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| John Hester | Bell Potter |
| Soo Romanoff | Edison Investment Research |
| Swayampakula Ramakanth | H.C. Wainwright & Co. |